Clinical Research Directory

Inclusion Criteria: Cohorts A, B and C: * Incident diagnosis of G/GEJ adenocarcinoma, as identified according to ICD-10 diagnosis codes (C16.x, C15.2, C15.5, C15.8, C15.9) and ICD for Oncology Third Edition (ICD-O-3) morphology codes (8140-8149, 8160-8162, 8190-8221, 8260-8337, 8350 8551, 8570-8576, 8940-8941) or data source equivalent. * At least 18 years of age at the date of 1L treatment initiation. Cohorts A and B: * Evidence of unresectable stage 3 or stage 4 disease. * Evidence of HER2(-) tumor any time prior to and including the date of 1L treatment initiation. * Evidence of CLDN18.2-positive tumor, defined as ≥75% of tumor cells showing moderate (2+) or strong (3+) membranous staining by IHC, assessed prior to or on the date of 1L treatment initiation. Cohort A only: * 1L treatment with zolbetuximab in combination with platinum-fluoropyrimidine doublet chemotherapy which begins during the patient enrolment period. Cohort B only: * 1L treatment that does not include zolbetuximab which begins during the patient enrolment period. Cohort C only: * Zolbetuximab administered during the patient enrolment period under any of the following off-label conditions: * NOT delivered in 1L for la/m disease and/or * NOT delivered in combination with platinum-fluoropyrimidine doublet, and/or * Delivered in combination with any systemic anti-cancer treatment that is not platinum-fluoropyrimidine doublet, and/or * NOT delivered to a patient with evidence of HER2(-) tumor any time prior to and including the date of zolbetuximab initiation, and/or * NOT delivered to a patient with evidence of CLDN18.2(+)-positive tumor, defined as ≥75% of tumor cells demonstrating moderate (2+) or strong (3+) membranous staining by IHC, assessed prior to or on the date of zolbetuximab initiation. Exclusion Criteria: Cohorts A, B and C: * Evidence of any other primary malignancy in the 5 years prior to and including the index date, as identified according to ICD-10 codes or data source equivalent and excluding non-melanoma skin cancer (ICD-10 code C44.x). Cohort A only: * Evidence that 1L treatment with zolbetuximab was received as part of a clinical trial. Cohort B only: * Evidence that 1L treatment was received as part of a clinical trial. Cohort C only: * Evidence that zolbetuximab was received as part of a clinical trial.